Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine in Children in Portugal

Gouveia, M; Fiorentino, F; Jesus, G; Costa, J; Borges, M

http://hdl.handle.net/10400.17/3234

Use this identifier to reference this record.

Name:	Description:	Size:	Format:
Ped Infect Dis J 2017_36_782.pdf		172.65 KB	Adobe PDF	Download

Send Feedback

Authors

Abstract(s)

Pneumococcal infections are the leading cause of vaccine-preventable death in children. In June 2015, the 13-valent pneumococcal conjugate vaccine (PCV13) was introduced in the Portuguese Immunization Program. We evaluated the cost-effectiveness of children vaccinated with PCV13 versus no vaccination for preventing pneumococcal diseases.

Keywords

Child, Preschool Cost-Benefit Analysis Humans Incidence Infant Immunization Models, Immunological Pneumococcal Infections Pneumococcal Vaccines CHLC FAR